BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 24125850)

  • 1. Mastering tricyclic ring systems for desirable functional cannabinoid activity.
    Petrov RR; Knight L; Chen SR; Wager-Miller J; McDaniel SW; Diaz F; Barth F; Pan HL; Mackie K; Cavasotto CN; Diaz P
    Eur J Med Chem; 2013 Nov; 69():881-907. PubMed ID: 24125850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and synthesis of a novel series of N-alkyl isatin acylhydrazone derivatives that act as selective cannabinoid receptor 2 agonists for the treatment of neuropathic pain.
    Diaz P; Xu J; Astruc-Diaz F; Pan HM; Brown DL; Naguib M
    J Med Chem; 2008 Aug; 51(16):4932-47. PubMed ID: 18666769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CB1 Knockout Mice Unveil Sustained CB2-Mediated Antiallodynic Effects of the Mixed CB1/CB2 Agonist CP55,940 in a Mouse Model of Paclitaxel-Induced Neuropathic Pain.
    Deng L; Cornett BL; Mackie K; Hohmann AG
    Mol Pharmacol; 2015 Jul; 88(1):64-74. PubMed ID: 25904556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 7-Azaindolequinuclidinones (7-AIQD): A novel class of cannabinoid 1 (CB1) and cannabinoid 2 (CB2) receptor ligands.
    Penthala NR; Shoeib A; Dachavaram SS; Cabanlong CV; Yang J; Zhan CG; Prather PL; Crooks PA
    Bioorg Med Chem Lett; 2020 Nov; 30(22):127501. PubMed ID: 32882418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic pain.
    Xu JJ; Diaz P; Astruc-Diaz F; Craig S; Munoz E; Naguib M
    Anesth Analg; 2010 Jul; 111(1):99-109. PubMed ID: 20522703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological data of cannabidiol- and cannabigerol-type phytocannabinoids acting on cannabinoid CB
    Navarro G; Varani K; Lillo A; Vincenzi F; Rivas-Santisteban R; Raïch I; Reyes-Resina I; Ferreiro-Vera C; Borea PA; Sánchez de Medina V; Nadal X; Franco R
    Pharmacol Res; 2020 Sep; 159():104940. PubMed ID: 32470563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and optimization of novel purines as potent and selective CB2 agonists.
    Hollinshead SP; Astles PC; Chambers MG; Johnson MP; Palmer J; Tidwell MW
    Bioorg Med Chem Lett; 2012 Aug; 22(15):4962-6. PubMed ID: 22765893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel pyridine derivatives as potent and selective CB2 cannabinoid receptor agonists.
    Chu GH; Saeui CT; Worm K; Weaver DG; Goodman AJ; Broadrup RL; Cassel JA; DeHaven RN; LaBuda CJ; Koblish M; Brogdon B; Smith S; Le Bourdonnec B; Dolle RE
    Bioorg Med Chem Lett; 2009 Oct; 19(20):5931-5. PubMed ID: 19736007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigations on the 4-quinolone-3-carboxylic acid motif. 6. Synthesis and pharmacological evaluation of 7-substituted quinolone-3-carboxamide derivatives as high affinity ligands for cannabinoid receptors.
    Pasquini S; De Rosa M; Ligresti A; Mugnaini C; Brizzi A; Caradonna NP; Cascio MG; Bolognini D; Pertwee RG; Di Marzo V; Corelli F
    Eur J Med Chem; 2012 Dec; 58():30-43. PubMed ID: 23085772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective CB2 receptor agonists. Part 3: the optimization of a piperidine-based series that demonstrated efficacy in an in vivo neuropathic pain model.
    Bartolozzi A; Cirillo PF; Berry AK; Hickey ER; Thomson DS; Wu L; Zindell R; Albrecht C; Ceci A; Gemkow MJ; Nagaraja NV; Romig H; Sauer A; Riether D
    Bioorg Med Chem Lett; 2015 Feb; 25(3):587-92. PubMed ID: 25575658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cannabinoid CB
    Li AL; Carey LM; Mackie K; Hohmann AG
    J Pharmacol Exp Ther; 2017 Aug; 362(2):296-305. PubMed ID: 28592614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-affinity relationships and pharmacological characterization of new alkyl-resorcinol cannabinoid receptor ligands: Identification of a dual cannabinoid receptor/TRPA1 channel agonist.
    Brizzi A; Aiello F; Marini P; Cascio MG; Corelli F; Brizzi V; De Petrocellis L; Ligresti A; Luongo L; Lamponi S; Maione S; Pertwee RG; Di Marzo V
    Bioorg Med Chem; 2014 Sep; 22(17):4770-83. PubMed ID: 25065940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists.
    Ashton JC; Wright JL; McPartland JM; Tyndall JD
    Curr Med Chem; 2008; 15(14):1428-43. PubMed ID: 18537620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo pharmacology of synthetic olivetol- or resorcinol-derived cannabinoid receptor ligands.
    Cascio MG; Bisogno T; Palazzo E; Thomas A; van der Stelt M; Brizzi A; de Novellis V; Marabese I; Ross R; van de Doelen T; Brizzi V; Pertwee R; Maione S; Di Marzo V
    Br J Pharmacol; 2006 Oct; 149(4):431-40. PubMed ID: 16953186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and binding studies of new potent ligands of cannabinoid receptors.
    Brizzi A; Brizzi V; Cascio MG; Bisogno T; Sirianni R; Di Marzo V
    J Med Chem; 2005 Nov; 48(23):7343-50. PubMed ID: 16279794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tricyclic Pyrazole-Based Compounds as Useful Scaffolds for Cannabinoid CB
    Asproni B; Murineddu G; Corona P; Pinna GA
    Molecules; 2021 Apr; 26(8):. PubMed ID: 33917187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional characterization and analgesic effects of mixed cannabinoid receptor/T-type channel ligands.
    You H; Gadotti VM; Petrov RR; Zamponi GW; Diaz P
    Mol Pain; 2011 Nov; 7():89. PubMed ID: 22093952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats.
    Rahn EJ; Makriyannis A; Hohmann AG
    Br J Pharmacol; 2007 Nov; 152(5):765-77. PubMed ID: 17572696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of spinal cannabinoid CB2 receptors inhibits neuropathic pain in streptozotocin-induced diabetic mice.
    Ikeda H; Ikegami M; Kai M; Ohsawa M; Kamei J
    Neuroscience; 2013 Oct; 250():446-54. PubMed ID: 23892011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective CB2 receptor agonists. Part 2: Structure-activity relationship studies and optimization of proline-based compounds.
    Riether D; Zindell R; Wu L; Betageri R; Jenkins JE; Khor S; Berry AK; Hickey ER; Ermann M; Albrecht C; Ceci A; Gemkow MJ; Nagaraja NV; Romig H; Sauer A; Thomson DS
    Bioorg Med Chem Lett; 2015 Feb; 25(3):581-6. PubMed ID: 25556092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.